跳至主要内容
临床试验/NCT00919373
NCT00919373已完成不适用

Substrate Modification in Stable Ventricular Tachycardia in Addition to ICD Therapy

Abbott Medical Devices32 个研究点 分布在 4 个国家目标入组 110 人开始时间: 2002年7月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
110
试验地点
32
主要终点
recurrence of any sustained clinical VT, stable or unstable, monomorphic or polymorphic, including VF, during the follow-up period

研究概览

简要总结

The main objective of this study is to compare the time from randomization to the first recurrence of any ventricular tachycardia (VT) in patients undergoing VT ablation (for stable VTs) and substrate ablation (for unstable VTs) after an initial episode of stable VT and patients not undergoing ablation, with both groups under the protection of an ICD.

详细描述

The main objective of this study is to compare the time from randomization to the first recurrence of any VT in patients undergoing VT ablation (for stable VTs) and substrate ablation (for unstable VTs) after an initial episode of stable VT and patients not undergoing ablation, with both groups under the protection of an ICD.

Prior to the ablation, the patients will undergo electrophysiologic study (EPS) with programmed ventricular stimulation, with the aim to reproduce the clinical VT. Most patients with coronary artery disease, systolic LV dysfunction, and one episode of clinical sustained VT have more than one inducible VT at electrophysiologic study. Since any inducible VT can become a potential clinical VT (24), an attempt will be made to ablate the clinical stable VT, as well as all inducible morphologies, stable or unstable.

One of the following 2 ablation strategies will be possible for each VT:

  • Substrate modification in sinus rhythm in case of unstable induced monomorphic VT which does not allow mapping and ablation in tachycardia, or noninducible stable clinical VT.
  • VT ablation in tachycardia in case of stable VT

For each procedure the number of tachycardias , the type of each tachycardia (inducible or noninducible, stable or unstable), the ablation strategy for each tachycardia (it is possible that lesions deployed for one tachycardia will render another tachycardia noninducible as well) and the procedural outcome for each tachycardia will be documented.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Coronary artery disease For the purpose of this study, coronary artery disease will be defined as the presence of a 50 % or more diameter stenosis of the left main coronary artery, or 75 % or more diameter stenosis of the left anterior descending, circumflex or right coronary arteries, or the history of a surgical or percutaneous revascularization procedure, or history of successful thrombolysis, or a history of prior myocardial infarction (e.g.: documented by Q-wave, R-reduction, aneurysm)
  • Left ventricular ejection fraction ≤ 50 % as estimated by echocardiography or contrast ventriculography within the previous 30 days and evidence for old myocardial infarction (ECG, echocardiographic or venticulographic).
  • One episode of documented stable clinical VT without any reversible causes
  • Written informed consent

排除标准

  • Age < 18 years or > 80 year
  • Protruding LV thrombus on pre-ablation echocardiogram
  • Acute myocardial infarction within the preceding 1 months
  • Class IV NYHA heart failure
  • Valvular heart disease or mechanical heart valve precluding access to the left ventricle
  • Unstable angina
  • Cardiac surgery involving cardiotomy (not CABG) within the past 2 months
  • Serum creatinine > 220 mmol/L (2.5 mg/dL)
  • Thrombocytopenia or coagulopathy
  • Contraindication to heparin
  • Pregnancy
  • Acute illness or active systemic infection
  • Other disease process likely to limit survival to less than 12 months
  • Significant medical problem that in the opinion of the principal investigator would preclude enrollment in the study
  • Participation in another investigational study
  • Unwillingness to participate or lack of availability for follow-up
  • Incessant VT or electrical storm
  • Bundle branch reentry tachycardia as the presenting VT
  • Preexisting ICD

研究组 & 干预措施

ICD-Implantation

Active Comparator

Implantation of an Implantable Cardioverter Defibrillator (ICD) alone.

干预措施: ICD Implantation (Procedure)

ICD + Ablation

Active Comparator

Stratified Catheter Ablation of Ventricular Tachycardia and ICD Implantation

干预措施: Substrate modification (Procedure)

ICD + Ablation

Active Comparator

Stratified Catheter Ablation of Ventricular Tachycardia and ICD Implantation

干预措施: VT ablation (Procedure)

ICD + Ablation

Active Comparator

Stratified Catheter Ablation of Ventricular Tachycardia and ICD Implantation

干预措施: ICD Implantation (Procedure)

结局指标

主要结局

recurrence of any sustained clinical VT, stable or unstable, monomorphic or polymorphic, including VF, during the follow-up period

时间窗: 2 years

次要结局

  • Number of adequate ICD interventions (shocks and overdrive episodes caused by recurrence of VT or VF and not supraventricular arrhythmias or mechanical lead problems).(2 years)
  • Severe clinical events (death, number of syncopes, number of hospital admissions for a cardiac indication, number of episodes of electrical storm (more than 3 VT episodes in 24 hours)) during the follow-up period .(2 years)
  • Quality of life(2 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (32)

Loading locations...

相似试验

Substrate Modification in Stable Ventricular... | 临床试验